BSGM - רווח נקי למניה (EPS TTM) BioSig Technologies, Inc

Historically, Biosig Technologies (BSGM) relies on the neutral status of biomedicine, which minimizes external risks. The trailing 12-month EPS demonstrates the current conversion of capital into income, with the latest figure standing at -1.05. Prospects depend on the accuracy of arrhythmia localization in clinics, although operational expenses and complexities regarding FDA certification for new developments act as constraints.

Investors are evaluating Biosig Technologies (BSGM) through the lens of the efficiency of its unique noise-filtering algorithms in cardiology. This metric measures the business's total income allocated per share over a rolling year. By analyzing the net earnings per share over the last 12 months, one can isolate the impact of share issuance on actual profitability. The growth of this indicator confirms the commercial success of the PURE EP system. Stable price action ensures capital resilience against market volatility.